Close Menu

Regulus

NEW YORK (GenomeWeb) — Regulus Therapeutics this week released interim results from an ongoing Phase I study of its microRNA-targeting hepatitis C therapy RG-101, which showed that a single subcutaneous dose of the drug could trigger an average 4.1-log reduction in viral loads in patients — a num

NEW YORK (GenomeWeb) – Regulus Therapeutics announced last week that it has initiated a natural history of disease study, called ATHENA, in patients with Alport syndrome.

Title: Nucleic Acid Microparticles for Pulmonary Delivery
Patent Number: 8,808,747
Filed: April 17, 2008

NEW YORK (GenomeWeb) – Officials from Regulus Therapeutics this week provided updates for the company's two lead drug candidates, stating that a Phase I study of its hepatitis C treatment RG-101 is set to yield key data in the next few months, while the preclinical Alport syndrome therapy RG-012

NEW YORK (GenomeWeb) – Regulus Therapeutics today announced a new collaborative agreement with Biogen Idec to identify microRNAs for multiple sclerosis.

NEW YORK (GenomeWeb) – New data published this month by researchers from Regulus Therapeutics and academic collaborators show that long-term therapeutic silencing of microRNA-33 could result in a number of deleterious effects in mice including fatty liver and elevated triglyceride levels.

NEW YORK (GenomeWeb) – Regulus Therapeutics this week announced that the US Food and Drug Administration has granted orphan drug status to the company's preclinical Alport syndrome therapy RG-012.

NEW YORK (GenomeWeb) – Microlin Bio is pushing ahead with its bid to go public on the Nasdaq, disclosing last week that it now expects to float roughly 4.3 million shares for between $6.50 and $7.50 apiece, which would raise as much as $32.3 million for the microRNA therapeutics and diagnostics s

Regulus Therapeutics has appointed Paul Grint as its chief medical officer.

NEW YORK (GenomeWeb) – As its recently established microRNA biomarker division makes gains with both partnered and in-house programs, Regulus Therapeutics is weighing the possibility of spinning off the unit as a standalone company that would develop and market clinical assays based on the small,

Pages

23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.

He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.

Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.

In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.